close 74% van de retail beleggers lijdt verlies op de handel in CFD`s met deze aanbieder. Investeringen brengen risico`s met zich mee en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 74% van de retail beleggers lijdt verlies op de handel in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

MDT

87.13

-1.01%ā†“

A

119.41

-0.9%ā†“

VEEV

167.53

+5.63%ā†‘

HQY

83.87

+3.38%ā†‘

TLRY

6.95

+0.43%ā†‘

MDT

87.13

-1.01%ā†“

A

119.41

-0.9%ā†“

VEEV

167.53

+5.63%ā†‘

HQY

83.87

+3.38%ā†‘

TLRY

6.95

+0.43%ā†‘

MDT

87.13

-1.01%ā†“

A

119.41

-0.9%ā†“

VEEV

167.53

+5.63%ā†‘

HQY

83.87

+3.38%ā†‘

TLRY

6.95

+0.43%ā†‘

MDT

87.13

-1.01%ā†“

A

119.41

-0.9%ā†“

VEEV

167.53

+5.63%ā†‘

HQY

83.87

+3.38%ā†‘

TLRY

6.95

+0.43%ā†‘

MDT

87.13

-1.01%ā†“

A

119.41

-0.9%ā†“

VEEV

167.53

+5.63%ā†‘

HQY

83.87

+3.38%ā†‘

TLRY

6.95

+0.43%ā†‘

Home惻Aandelen Lijst惻Thermo Fisher Scientific Inc
Search

Thermo Fisher Scientific Inc

Gesloten

SectorGezondheidszorg

531.41 0.67

Strong Buy

Prijsupdate 15 apr 2026, 19:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

523.19

Max

532.72

Belangrijke statistieken

By Trading Economics

Inkomsten

349M

2B

Verkoop

1.1B

12B

K/W

Sectorgemiddelde

27.519

66.418

Dividendrendement

0.35

Winstmarge

16.128

Werknemers

125,000

EBITDA

377M

3.2B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+28.28% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-54B

181B

Vorige openingsprijs

530.74

Vorige sluitingsprijs

531.41

Nieuwssentiment

By Acuity

26%

74%

84 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

406.5 / 417.79 Steun & Weerstand

Thermo Fisher Scientific Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 jan 2026, 11:34 UTC

Winsten

Thermo Fisher 4Q Profit Rises as Biopharma Spending Rebounds

DJ

Lezen

29 okt 2025, 10:51 UTC

Acquisities, Fusies, Overnames

Thermo Fisher Scientific Agrees to Buy Clario Holdings for $8.88 billion

DJ

Lezen

23 okt 2025, 20:49 UTC

Winsten

Correction to Thermo Fisher Article on Oct. 22

DJ

Lezen

22 okt 2025, 10:28 UTC

Winsten

Thermo Fisher 3Q Revenue Rises, Boosted by Life Sciences Business

DJ

Lezen

24 mrt 2026, 12:04 UTC

Acquisities, Fusies, Overnames

Thermo Fisher Completes Acquisition of Clario Holdings for $8.875 Billion >TMO

DJ

Lezen

24 mrt 2026, 12:00 UTC

Acquisities, Fusies, Overnames

Thermo Fisher Scientific Completes Acquisition Of Clario Holdings, Inc. >TMO

DJ

Lezen

29 jan 2026, 11:01 UTC

Winsten

Thermo Fisher 4Q Organic Revenue Rose 3% >TMO

DJ

Lezen

29 jan 2026, 11:00 UTC

Winsten

Thermo Fisher: Entering 2026 From Position of Strength >TMO

DJ

Lezen

29 jan 2026, 11:00 UTC

Winsten

Thermo Fisher 4Q Net $1.96B >TMO

DJ

Lezen

29 jan 2026, 11:00 UTC

Winsten

Thermo Fisher 4Q Rev $12.22B >TMO

DJ

Lezen

29 jan 2026, 11:00 UTC

Winsten

Thermo Fisher 4Q EPS $5.21 >TMO

DJ

Lezen

29 jan 2026, 11:00 UTC

Winsten

Thermo Fisher 4Q Adj EPS $6.57 >TMO

DJ

Lezen

29 okt 2025, 10:06 UTC

Acquisities, Fusies, Overnames

Thermo Fisher: Clario Provides Endpoint Data Solutions for Clinical Trials >TMO

DJ

Lezen

29 okt 2025, 10:05 UTC

Acquisities, Fusies, Overnames

Thermo Fisher: Claro Deal Includes Potential Additional Earnout, Other Payments >TMO

DJ

Lezen

29 okt 2025, 10:05 UTC

Acquisities, Fusies, Overnames

Thermo Fisher to Buy Clario From Group Led by Astorg and Nordic Cap, Novo Holding, Cinven >TMO

DJ

Lezen

29 okt 2025, 10:04 UTC

Acquisities, Fusies, Overnames

Thermo Fisher Scientific to Pay $8.875 Billion at Closing for Clario Holdings >TMO

DJ

Lezen

29 okt 2025, 10:00 UTC

Acquisities, Fusies, Overnames

Thermo Fisher Scientific to Acquire Clario Holdings >TMO

DJ

Lezen

22 okt 2025, 10:01 UTC

Winsten

Thermo Fisher 3Q Organic Revenue Rose 3% >TMO

DJ

Lezen

22 okt 2025, 10:00 UTC

Winsten

Thermo Fisher: In Great Position to Deliver on 2025 Objectives >TMO

DJ

Lezen

22 okt 2025, 10:00 UTC

Winsten

Thermo Fisher 3Q Adj EPS $5.79 >TMO

DJ

Lezen

22 okt 2025, 10:00 UTC

Winsten

Thermo Fisher 3Q Rev $11.12B >TMO

DJ

Lezen

22 okt 2025, 10:00 UTC

Winsten

Thermo Fisher 3Q Net $1.62B >TMO

DJ

Lezen

22 okt 2025, 10:00 UTC

Winsten

Thermo Fisher 3Q EPS $4.27 >TMO

DJ

Lezen

2 sep 2025, 12:15 UTC

Acquisities, Fusies, Overnames

Thermo Fisher Scientific Completes Acquisition Of Sanofi's Ridgefield, New Jersey Site >TMO

DJ

Lezen

2 sep 2025, 12:08 UTC

Acquisities, Fusies, Overnames

Solventum Had Seen 2025 Adjusted EPS $5.80-$5.95 >SOLV

DJ

Lezen

2 sep 2025, 12:08 UTC

Acquisities, Fusies, Overnames

Solventum Raises 2025 View To Adj EPS $5.88-Adj EPS $6.03 >SOLV

DJ

Lezen

2 sep 2025, 12:04 UTC

Acquisities, Fusies, Overnames

Solventum to Use Net Proceeds Primarily to Pay Down Debt >SOLV

DJ

Lezen

2 sep 2025, 12:03 UTC

Acquisities, Fusies, Overnames

Solventum Closes Sale of Unit to Thermo Fisher for $4 Billion in Cash >SOLV

DJ

Lezen

2 sep 2025, 12:03 UTC

Acquisities, Fusies, Overnames

Thermo Fisher Completes Acquisition of Purification & Filtration Business of Solventum for About $4B in Cash >TMO

DJ

Lezen

2 sep 2025, 12:00 UTC

Acquisities, Fusies, Overnames

Solventum Completes Sale of Purification & Filtration Business to Thermo Fisher Scientific >SOLV TMO

DJ

Lezen

Peer Vergelijking

Prijswijziging

Thermo Fisher Scientific Inc Prognose

Koersdoel

By TipRanks

28.28% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 659.64Ā USDĀ  28.28%

Hoogste 710Ā USD

Laagste 575Ā USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Thermo Fisher Scientific Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

12

Buy

2

Hold

0

Sell

Gebaseerd op 14 analisten die aandelenratings hebben gegeven aan Thermo Fisher Scientific Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

406.5 / 417.79Steun & Weerstand

Korte Termijn

Bearish Evidence

Recent bearish events outweigh bullish events.

Gemiddeld Termijn

Bearish Evidence

There is one bearish event.

Lange Termijn

Strong Bearish Evidence

All events are bearish.

Sentiment

By Acuity

84 / 348 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

$

Over Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar

Andere aandelen uit de sector

MDT

Medtronic PLC

87.13

ā†“-1.01%

A

Agilent Technologies Inc

119.41

ā†“-0.9%

VEEV

Veeva Systems Inc

167.53

ā†‘ +5.63%

HQY

HealthEquity Inc

83.87

ā†‘ +3.38%

TLRY

Tilray Brands Inc

6.95

ā†‘ +0.43%
help-icon Live chat